Cassava Sciences, Inc. (SAVA)
Largest Insider Buys in Sector
SAVA Stock Price History Chart
SAVA Stock Performance
About Cassava Sciences, Inc.
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, …
Insider Activity of Cassava Sciences, Inc.
Over the last 12 months, insiders at Cassava Sciences, Inc. have bought $0 and sold $253,948 worth of Cassava Sciences, Inc. stock.
On average, over the past 5 years, insiders at Cassava Sciences, Inc. have bought $2.92M and sold $253,948 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 30,000 shares for transaction amount of $523,500 was made by ROBERTSON SANFORD (director) on 2023‑08‑23.
List of Insider Buy and Sell Transactions, Cassava Sciences, Inc.
| 2024-11-29 | Sale | Chief Financial Officer | 61,800 0.1291% | $3.86 | $238,468 | -24.74% | ||
| 2024-11-29 | Sale | Chief Medical Officer | 4,000 0.0084% | $3.87 | $15,480 | -24.74% | ||
| 2023-08-23 | director | 30,000 0.0716% | $17.45 | $523,500 | +23.16% | |||
| 2023-08-22 | director | 16,571 0.0382% | $16.65 | $275,907 | +24.23% | |||
| 2023-08-21 | director | 1,906 0.0046% | $16.80 | $32,021 | +27.38% | |||
| 2023-03-07 | director | 77,276 0.1893% | $25.76 | $1.99M | -9.92% | |||
| 2023-03-06 | director | 11,565 0.0275% | $26.13 | $302,193 | -13.62% | |||
| 2022-08-23 | 36,159 0.0849% | $23.79 | $860,223 | +3.97% | ||||
| 2022-08-23 | Chief Clinical Dev. Officer | 2,500 0.006% | $24.44 | $61,100 | +3.97% | |||
| 2022-08-12 | 100,000 0.253% | $20.69 | $2.07M | +29.04% | ||||
| 2022-08-12 | Chief Financial Officer | 2,500 0.0061% | $19.95 | $49,875 | +29.04% | |||
| 2020-09-24 | President and CEO | 10,000 0.0395% | $9.59 | $95,900 | +369.31% | |||
| 2020-09-18 | director | 36,281 0.1287% | $8.92 | $323,627 | +341.71% | |||
| 2020-09-17 | director | 213,719 0.8426% | $6.98 | $1.49M | +527.36% | |||
| 2020-09-17 | Chief Financial Officer | 12,000 0.0477% | $7.03 | $84,380 | +527.36% | |||
| 2019-12-31 | President and CEO | 100,000 0.4344% | $5.53 | $553,000 | +31.73% | |||
| 2019-12-26 | President and CEO | 10,000 0.0567% | $4.15 | $41,500 | +65.01% | |||
| 2019-12-20 | director | 423,788 2.2827% | $2.20 | $932,334 | +172.00% | |||
| 2019-12-19 | director | 76,212 0.411% | $1.86 | $141,754 | +222.11% | |||
| 2019-12-19 | Chief Financial Officer | 5,300 0.0289% | $1.88 | $9,964 | +222.11% |
Insider Historical Profitability
| Schoen Eric | Chief Financial Officer | 0 0% | $2.42 | 4 | 1 | +278.2% |
| Kupiec James William | Chief Medical Officer | 0 0% | $2.42 | 1 | 1 | +3.97% |
| BLACK BEAR OFFSHORE MASTER FUND LP | 10 percent owner | 5810453 12.0773% | $2.42 | 71 | 9 | +9.41% |
| EASTBOURNE CAPITAL MANAGEMENT LLC/CA | 10 percent owner | 3230204 6.7141% | $2.42 | 10 | 17 | <0.0001% |
| BARBIER REMI | President and CEO | 1078855 2.2425% | $2.42 | 6 | 112 | +182.87% |
Institutional Investor Ownership
| BlackRock | $61.79M | 6.35 | 3.05M | +0.27% | +$163,314.21 | <0.01 | |
| The Vanguard Group | $47.81M | 4.91 | 2.36M | +1.37% | +$646,317.66 | <0.01 | |
| State Street | $22.19M | 2.28 | 1.09M | +2.23% | +$483,490.42 | <0.01 | |
| Geode Capital Management | $18.3M | 1.88 | 901,840 | +3.19% | +$565,030.69 | <0.01 | |
| Gallacher Capital Management Llc | $11.88M | 1.22 | 585,381 | +0.65% | +$76,594.72 | 6.39 |